Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 
Home > News > Trial News

Trial News 

16.04.2019 

Clinical Trials

33. Schweizer Frauenlauf Bern, June 16, 2019
JOIN the IBCSG PINK LADIES

Women 4 Women - walking together stronger than ever
PINK.Ladies@ibcsg.org

 

We are happy to share the POSITIVE PROGRESS, Vol. 2, Februar 2019.


We are pleased to share the attached February 2019 IBCSG Circular Letter.
This issue includes:
* Highlights from SABCS 2018
* Trial Analysis- Past and Future
* Trial Updates, including the activation of POLAR
* 2018 Publication List
* Information about the upcoming Annual Meeting in Vienna

 

IBCSG 23-01 NEJM Journal Watch - Summary and Comment
Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer
William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5  


Publications:                

374. Regan MM, Fleming GF, Walley B, Francis PA, Pagani O. Adjuvant systemic treatment of premenopausal women with hormone receptor–positive early breast cancer: Lights and shadows. J Clin Oncol 2019 April 10;37(11)862-866. doi: 10.1200/JCO.18.02433. Epub 2019 Feb 27. (IBCSG 24-02, 25-02) (Journal Impact Factor 26.303).

373. Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi RM. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. Breast Cancer Res 2019 Feb 22;21(1)30. doi: 10.1186/s13058-019-1118-z. (BIG 1-98) (Journal Impact Factor 6.142)

372. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol 2019 Mar 1;37(7)559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16. (IBCSG 22-00) (Journal Impact Factor 26.303).

371. Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multi-centre, phase 1b-2 trial. Lancet Oncol. doi: 10.1016/S1470-2045(18)30812-X. 2019 February 11. [Epub ahead of print] (IBCSG 45-13) (Journal Impact Factor 36.418).

The manuscript is attached and The Lancet Oncology link is here: https://doi.org/10.1016/S1470-2045(18)30812-X

 

News

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

08.09.2019:
8.9.2019 - RACE FOR LIFE, Bundesplatz Bern

16.06.2019:
33. SCHWEIZER FRAUENLAUF 16. Juni 2019 woman 4 woman - walking together, stronger than ever

All News

 
  Print